Precision BioSciences, Inc.
DTIL
$6.30
$0.6311.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.12% | -99.07% | -98.56% | -11.11% | 40.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.12% | -99.07% | -98.56% | -11.11% | 40.98% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -50.12% | -99.07% | -98.56% | -11.11% | 40.98% |
| SG&A Expenses | -1.81% | -0.90% | 1.54% | -3.15% | -10.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.90% | -1.21% | -3.75% | 3.40% | 2.59% |
| Operating Income | -99.33% | -452.28% | -1,135.40% | -27.53% | 40.18% |
| Income Before Tax | -750.33% | -828.37% | -595.50% | -9.99% | 116.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -750.33% | -828.37% | -595.50% | -9.99% | 116.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -737.98% | -1,069.52% | -561.16% | 20.54% | 111.69% |
| EBIT | -99.33% | -452.28% | -1,135.40% | -27.53% | 40.18% |
| EBITDA | -122.69% | -634.12% | -3,981.85% | -45.06% | 38.36% |
| EPS Basic | -366.33% | -10,630.08% | -3,944.18% | 73.88% | 112.00% |
| Normalized Basic EPS | -350.05% | -1,731.74% | -2,130.45% | 67.42% | 118.29% |
| EPS Diluted | -371.23% | -16,420.39% | -4,486.42% | 73.46% | 111.80% |
| Normalized Diluted EPS | -354.23% | -1,838.95% | -1,966.04% | 66.91% | 118.01% |
| Average Basic Shares Outstanding | 87.48% | 73.41% | 80.76% | 90.67% | 79.78% |
| Average Diluted Shares Outstanding | 87.59% | 73.06% | 80.33% | 90.91% | 80.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |